Proinflammatory cytokines have been proposed as potential targets for the management of RITIs.115 Clinically, neutralizing antibodies that can block IL-17, IL-17RA, and/or IL-17RC signals have been widely used and shown a reduced severity and improved remission in inflammatory diseases such as inflammatory bowel diseases, psoriatic arthritis, rheumatoid arthritis, and systemic lupus erythematosus.30,116. The gene discussed is IL17RC; the disease is inflammatory bowel disease.